Antiprotozoal Lysophospholipid Analogues: A Comparison of their Activity Against Trypanosomatid Parasites and Tumor Cells

Author(s): S. L. de Castro, R. M. Santa-Rita, J. A. Urbina, S. L. Croft.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 4 , Issue 2 , 2004

Become EABM
Become Reviewer


Lysophospholipid analogues (LPAs), originally developed as anti-cancer agents, have shown significant activity against Leishmania spp. and Trypanosoma cruzi, both in vitro and in vivo. Miltefosine, used as a topical formulation (Miltex™) for metastases, was registered in 2002 for the oral treatment of visceral leishmaniasis. LPAs interfere with lipid synthesis in T. cruzi and cancer cells, but the activity is about > 20- fold higher against the parasite.

Keywords: Antiprotozoal, Lysophospholipid, Trypanosoma cruzi, leishmaniasis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [141 - 151]
Pages: 11
DOI: 10.2174/1389557043487439
Price: $58

Article Metrics

PDF: 7